Faeth Therapeutics partners with Roche on Phase 1b/2 trial of PIKTOR combination in advanced breast cancer
Faeth Therapeutics and Roche will evaluate PIKTOR with investigational breast cancer drug giredestrant in a planned Phase 1b/2 trial for patients with hormone receptor-positive, HER2-negative advanced breast cancer.
1. Trial collaboration
Faeth Therapeutics will sponsor and conduct the trial, retaining all rights to PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib. Roche will supply giredestrant.





